Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Needham's Mike Cikos downgraded VRNS to Hold from Buy on Thursday, flagging execution risk tied to reported Proofpoint acquisition talks and headwinds from the ongoing SaaS transition. The move lands ten days before Varonis reports earnings on 26 October. It sits against a backdrop where short sellers are retreating and options traders are leaning bullish.
Needham's downgrade is the notable outlier in a week of constructive analyst activity. Wells Fargo's Richard Poland kept his Overweight and lifted his target from $48 to $53. TD Cowen's Shaul Eyal raised his Buy target to $56 from $53, also this week. Consensus sits at a Hold with a mean price target of $51.76, implying 8.2% upside to Thursday's close of $47.34.
The bull case rests on Varonis's near-complete SaaS transition. About 89% of ARR is now on SaaS, renewal rates are above 90%, and management raised full-year growth guidance to 20 to 21%. The bear case, as Needham frames it, centres on distraction risk from the Proofpoint talks hitting at a critical point in the sales quarter, alongside competitive pressure from CrowdStrike, Palo Alto Networks, and Zscaler.
Short interest has fallen sharply. SI % of free float dropped 19% over the past week to 5.2%, its lowest level since early September, and is down 27.6% over the past month. The borrow market remains loose: availability stands at 2,547%, meaning there are roughly 25 shares available to borrow for every one currently shorted. The ORTEX short score has also eased, dropping from 44.5 to 40.5 over the past week, reflecting the lighter positioning.
The put-call ratio has been trending steadily lower since early October. It hit 0.48 on Wednesday, 1.9 standard deviations below its 20-day mean of 0.58. Calls are outpacing puts by a widening margin as the earnings date approaches. The 52-week low for the PCR is 0.18, so there is room to move further in either direction, but the direction of travel is clearly toward call-side demand.
BlackRock added 1.48 million shares in the quarter to 30 September, lifting its stake to 11.1% of shares outstanding. The two most recent earnings prints produced one-day moves of -12.9% and -2.3%. With Needham stepping to the sidelines and the Proofpoint story unresolved, the 26 October print is likely to be the clearest near-term read on whether the bull case holds.
Data summary
See the live data behind this article on ORTEX.
Open VRNS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
